Prescribing information

 

This website is intended for healthcare professionals. Please do not direct patients to this page.

These resources have been developed by Novartis and are intended for healthcare professionals, to help you get the most out of treating with JAKAVI®.

Box 1: image of the real-world evidence  pdf with colourless couple on the sofa beside the couple in colour

Real-world treatment evidence

Real-world insights and findings from a UK physician survey on the use of the BSH guidelines for the diagnosis and management of MF

Download

Box 2: Image of Jakavi dosing timeline

JAKAVI® dosing timeline

A JAKAVI® treatment timeline that can be used during your patient consultations

Download

 

Box 3: Image of  pdf for MF risk stratification with IPSS, DIPSS and DIPSS Plus

MF risk stratification with IPSS, DIPSS and DIPSS Plus

Download

Box 3: Image of  pdf for MF risk stratification with IPSS, DIPSS and DIPSS Plus

JAKAVI® practical management guide

Practical information and advice on using JAKAVI® and managing adverse events

Download

 

 

For full product information, please refer to the Summary of Product Characteristics.

 

These resources have been developed by Novartis and are intended for patients who have been diagnosed with an MPN. These resources will help give patients the confidence and knowledge to discuss their disease and track symptoms effectively. Information provided in these resources should not be considered an alternative to advice from a healthcare professional.

Image of Cosentyx digital patient pack

MPN10 Patient Brochure

A brochure specifically designed to help MPN patients record how their symptoms change over time

Download

Image of Cosentyx digital patient pack

MPN10 Tracker website

An online tool where patients can record and track changes in symptoms over time

Visit

 

Video: A guide to tracking MPN symptoms with Prof. Claire Harrison

 

Image of Cosentyx digital patient pack

Patient Symptom Guide

A guide to help patients identify and better understand symptoms related to their disease

Download

Image of Cosentyx digital patient pack

Understanding MPNs: A Guide

An infographic that explains disease facts and medical terms that patients might encounter during or after diagnosis

Download

Image of Cosentyx digital patient pack

MPN Patient Resource webpage

An online hub where patients can download all of these resources and learn more about their disease

Visit

 

JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1

BSH, British Society for Haematology; DIPSS, Dynamic International Prostate Symptom Score; HCP, healthcare professional; IPSS, International Prostate Symptom Score; MF, myelofibrosis; MPN, myeloproliferative neoplasm.

  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
Rate this content: 
No votes yet
UK | May 2021 | 119382
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]